Two Seas Capital LP Acquires 2,152,797 Shares of Esperion Therapeutics, Inc. $ESPR

Two Seas Capital LP raised its holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 22.1% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 11,902,521 shares of the biopharmaceutical company’s stock after purchasing an additional 2,152,797 shares during the quarter. Esperion Therapeutics accounts for about 0.9% of Two Seas Capital LP’s holdings, making the stock its 13th biggest position. Two Seas Capital LP’s holdings in Esperion Therapeutics were worth $44,039,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. KFG Wealth Management LLC bought a new stake in Esperion Therapeutics in the fourth quarter valued at approximately $37,000. Cary Street Partners Financial LLC bought a new stake in Esperion Therapeutics in the fourth quarter valued at approximately $38,000. Larson Financial Group LLC bought a new stake in Esperion Therapeutics in the fourth quarter valued at approximately $39,000. Vanguard Personalized Indexing Management LLC acquired a new position in shares of Esperion Therapeutics in the third quarter valued at approximately $29,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in shares of Esperion Therapeutics by 49.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,617 shares of the biopharmaceutical company’s stock valued at $43,000 after purchasing an additional 3,822 shares during the last quarter. Institutional investors own 47.39% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on ESPR. Wall Street Zen raised Esperion Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, March 14th. HC Wainwright downgraded Esperion Therapeutics from a “buy” rating to a “neutral” rating and set a $3.16 target price on the stock. in a research report on Friday, May 1st. Jefferies Financial Group downgraded Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 1st. Cantor Fitzgerald downgraded Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 1st. Finally, Citizens Jmp downgraded Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 1st. One equities research analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Esperion Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $5.54.

Esperion Therapeutics Price Performance

Shares of NASDAQ:ESPR opened at $3.13 on Friday. The company has a market capitalization of $805.76 million, a P/E ratio of -52.17, a P/E/G ratio of 2.54 and a beta of 1.07. Esperion Therapeutics, Inc. has a 1 year low of $0.95 and a 1 year high of $4.18. The business’s 50 day simple moving average is $2.67 and its 200 day simple moving average is $3.13.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings results on Friday, May 8th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.08). The company had revenue of $80.10 million for the quarter, compared to analyst estimates of $84.52 million. Esperion Therapeutics had a negative return on equity of 0.14% and a net margin of 0.12%. On average, sell-side analysts anticipate that Esperion Therapeutics, Inc. will post 0.05 EPS for the current fiscal year.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.